| abstract |
(57) Summary The present invention relates to a selective inhibitor of mammalian osteoclast activity, a method for producing the same and a pharmaceutical composition comprising the same, and a method of treating the selective inhibitor for administration to a human or animal patient. The selective inhibitors have been found to inhibit vacuolar H + -ATPase, eg, vacuolar H + -ATPase in osteoclasts, and are therefore therapeutically useful for physiological disorders involving bone resorption. It is valid. In an embodiment of the present invention, the selective inhibitor comprises a nicotinonitrile compound of general formula (I). Embedded image |